

APPLICATION UNDER UNITED STATES PATENT LAWS

Atty. Dkt. No. PW 0283675/E 5153-01CW
(M#)

Invention: FAST DISINTEGRATING TABLETS AND METHOD FOR PRODUCTION THEREOF

Inventor (s): MATSUMOTO, Keiko
OHKUMA, Moriyuki
KATO, Yasutomi
OKUDA, Otomo

Pillsbury Winthrop LLP
Intellectual Property Group
1600 Tysons Boulevard
McLean, VA 22102
Attorneys
Telephone: (703) 905-2000

This is a:

- ☐ Provisional Application
- ☐ Regular Utility Application
- ☐ Continuing Application
- ☒ The contents of the parent are incorporated by reference
- ☒ PCT National Phase Application
- ☐ Design Application
- ☐ Reissue Application
- ☐ Plant Application
- ☐ Substitute Specification
- Sub. Spec Filed _____
in App. No. _____ / _____
- ☐ Marked up Specification re
Sub. Spec. filed _____
In App. No. _____ / _____

SPECIFICATION

DESCRIPTION

FAST DISINTEGRATING TABLETS AND METHOD FOR
PRODUCTION THEREOF

TECHNICAL FIELD

The present invention relates to surface-
modified powders comprising a pharmacologically active
ingredient and having a good flowability sufficient to
5 enable direct tabletting, a method for preparing the
surface-modified powders and use thereof, as well as
fast disintegrating tablets, which have a suitable
strength and dissolve instantly in the mouth when
holding water in the oral cavity, and a method of
10 producing the tablets using the surface-modified
powders comprising a pharmacologically active
ingredient.

BACKGROUND ART

Recently, research has been extensively
15 undertaken to develop orally dissolving preparations
having an appropriate disintegratability and solubility
to make oral medication easy to the elderly people and
infants.

According especially to the silver science
20 research conducted by the Japanese Ministry of Health
and Welfare, there is an interesting research report
entitled "Studies to manufacture new pharmaceutical

preparations and new packaging containers most suitable for administration to elderly people" (Masayasu Sugihara, et al., Tokyo Women's Medical College) (Yakuji Nippo, August 22, 1989 issue). The report
5 discloses buccal dissolution type preparations containing polyethylene glycol 1000 as the base that dissolves in the oral cavity, and oleaginous base as the base that melts at the temperature in the oral cavity, which preparations are obtained by filling the
10 pocket of a polyvinyl chloride molding sheet for press through package (PTP) use with a medicated base, and allowing to cool and mold.

Japanese Patent KOKAI (Laid-Open) No. 5-271054 discloses buccal dissolution type tablets having
15 a porous structure with a hardness of 2 to 25 kg and a porosity of about 20 to 80%, which are manufactured by tableting a composition comprising a pharmacologically active ingredient, a carbohydrate and water in an amount barely sufficient to wet the surface of
20 particles of the carbohydrate.

On the other hand, in certain countries, buccal dissolution type solid preparations, such as Zydis (trade name) from R. P. Scherer (England) etc., are commercially available. The Zydis preparation is
25 manufactured by blending a pharmacologically active ingredient, a polymer, sugar and other ingredients together, dissolving the blend and freeze-drying the solution (Manuf. Chemist., February 36, 1990).

However, since the buccal dissolution type tablets described above are administered by dissolving in the mouth on contact with saliva, these tablets are not necessarily compatible with practical dosing instructions in the actual medical scene, namely, the dosage form of giving a medicament with a cup of water. It is therefore concerned that confusion might be caused in the actual medical scene. Also, 2 or 3 kinds of drugs are simultaneously administered mostly in practical medication and even 5 or 6 kinds of drugs are given all together in some occasion. Then, it tends to occur such a case that only one medicament is taken without water because of its buccal dissolution tablet form but the other medicaments should be taken with water, which also tends to cause confusion.

The aforesaid methods for preparing buccal dissolution type tablets all involve difficulties in tablet preparation via complex procedures including heating, melting, dissolution, freezing and the like. It is thus desired to prepare buccal dissolution type tablets in a simple way, e.g., by dry granulation, direct tableting, etc.

However, since powdery active ingredients are poorly flowable, dry granulation technique has been used only for well-fluidizing pharmacologically active ingredients. Physically, direct tableting of ordinary active ingredients with a small bulk density and poor fluidizing properties is considered extremely difficult

since the direct tableting is greatly affected by the powder characteristics and proportion of pharmacologically active ingredients. Very few attempts to improve powder properties of a pharmacologically active ingredient at the final stage of overall synthesis steps have been hitherto made but the purpose was to avoid problems upon tableting. Actually, high dose preparations of a pharmacologically active ingredient are very rarely manufactured by direct tableting.

10 For these reasons, any report to study dry granulation and direct tableting of buccal dissolution type tablets has not yet been made.

DISCLOSURE OF INVENTION

Therefore, it is an object of the present invention to provide fast disintegrating tablets, which have a suitable disintegratability and solubility to be disintegrated to an appropriate size when holding water in the oral cavity so that the tablets are neither adhered to nor choked in the throat, and are easy for aged or pediatric patients to take medicaments, which can still maintain a mechanical strength sufficient to resist destruction in the course of manufacture and storage, and which also have an adequate strength to resist crumbling upon administration, for example, when they are taken out of PTP packages.

It is another object of the present invention to provide a method of producing fast disintegrating

tablets by dry granulation technique, in which tablets having the aforesaid excellent properties can be produced in a simple fashion, without requiring complex manufacturing procedures.

5 It is a further object of the present invention to provide surface-modified powders comprising a pharmacologically active ingredient having a good flowability, which enables to produce, by direct
10 tableting and dry granulation technique, the aforesaid fast disintegrating tablets that are readily taken by aged or pediatric patients and are thus practically useful.

 It is a further object of the present invention to provide a method for producing the surface-
15 modified powders comprising a pharmacologically active ingredient with a good flowability.

 It is a still further object of the present invention to provide use of surface-modified powders comprising a pharmacologically active ingredient for
20 producing tablets by direct tableting of the surface-modified powders comprising a pharmacologically active ingredient.

 It is a still further object of the present invention to provide a method of producing tablets,
25 which comprises producing tablets by direct tableting using the surface-modified powders comprising a pharmacologically active ingredient.

~~In view of the circumstances described above,~~

Sub
B1

Sub B1

the present inventors have made extensive investigations to develop tablets of fast disintegration type and found that, when a pharmacologically active ingredient is subjected to surface modification with a surface modifying base material such as light silicic anhydride, etc., the surface-modified powders comprising a pharmacologically active ingredient with a good flowability can be obtained. The inventors have further found that blending of the surface-modified powders comprising a pharmacologically active ingredient with a disintegrant such as partially alphanized starch, crospovidone, etc. followed by direct tableting provides fast or rapidly disintegrating tablets that maintain an adequate hardness and are yet rapidly disintegrated and dissolved in the oral cavity without resort to complex production procedures such as heating, melting, dissolving, freezing, etc.; these complex procedures are usually required for conventional production steps. Based on the above findings, the present invention has been accomplished.

Therefore, the present invention relates to surface-modified powders comprising a pharmacologically active ingredient having a flowability sufficient to enable direct tableting, the powders being surface-modified by subjecting powders for surface modification comprising a pharmacologically active ingredient or a pharmacologically active ingredient and a diluent to surface modification with a surface modifying base

material.

The present invention further relates to a method of producing pharmacologically active ingredient-comprising surface-modified powders, which
5 comprises blending powders for surface modification comprising a pharmacologically active ingredient or a pharmacologically active ingredient and a diluent with a surface modifying base material to modify the surface of the powders, whereby the pharmacologically active
10 ingredient-comprising surface-modified powders having flowability sufficient to enable direct tabletting are produced.

The present invention further relates to a fast disintegrating tablet obtained by blending the
15 pharmacologically active ingredient-comprising surface-modified powders described above with a disintegrant and directly tabletting the blend.

The present invention further relates to a method of producing a fast disintegrating tablet, which
20 comprises blending modifying powders comprising a pharmacologically active ingredient or a pharmacologically active ingredient and a diluent with a surface modifying base material to modify the surface of the powders thereby to prepare pharmacologically
25 active ingredient-comprising surface-modified powders having flowability sufficient to enable direct tabletting, then incorporating a disintegrant into the powders, and directly tabletting the mixture to produce

the fast disintegrating tablet.

The present invention further relates to use of pharmacologically active ingredient-comprising surface-modified powders for the production of tablets
5 by directly tableting the pharmacologically active ingredient-comprising surface-modified powders optionally after adding an additive(s) to the powders.

BEST MODE FOR CARRYING OUT THE INVENTION

The pharmacologically active ingredient for
10 use in the present invention may be in any optional form so long as the active ingredient takes a powdery form at ambient temperature. The active ingredient may also be in a crystalline or non-crystalline form. When pharmacologically active ingredients take no powdery
15 form at ambient temperature, these active ingredients may be converted into a powdery form at ambient temperature by adsorbing these active ingredients onto a porous carrier such as special calcium silicate, starch, etc.

20 Specifically, the pharmacologically active ingredients for use in the present invention may be at least one member selected from the group consisting of gastrointestinal function conditioning agents, antacids, analgesics, antiinflammatory agents, anti-
25 inflammatory-analgesic-antipyretic agents, antibacterial agents, antifungal agents, cardiotonics, inorganics preparations, therapeutic agents for

digestive ulcer, coronary vasodilators, peripheral vasodilators and cerebrovasodilators, anti-infectives, anti-anxiety drugs, neuroleptic agents, central nervous system stimulants, antidepressants, antihistamines, antidiarrheal preparations, mild laxatives, nourishing and health-promoting agents, cholesterol lowering agents, spasmolytics, antiagony agents, heart rhythm regulators, therapeutic agents for arterial hypertension, antimigraine agents, blood coagulation regulators, therapeutic agents for thyroid dysfunction, diuretics, appetite suppressants, antiasthmatics, antitussives, expectorants, sedative expectrants, mucus controlling agents, antiemetics, anti-uricemic agents, therapeutic agents for gout, antiarrhythmic drugs, therapeutic drugs for hyperglycemia, bronchodilators, antidiabetic agents, oral contraceptives, therapeutic drugs for travel sickness, therapeutic drugs for prostatic hypertrophy, therapeutic drugs for pancreatitis, hypnotic inducers, hypnotic-sedative agents, antirheumatoid agents, antiepileptics, cerebral metabolism improving agents, anti-platelet drugs, vitamins, and so on.

More specifically, there are antacids such as calcium carbonate, sodium hydrogencarbonate, magnesium oxide, etc.; antiinflammatory agents such as diclofenac sodium, ketoprofen, indomethacin, flurbiprofen, etc.; analgesic-antipyretic agents such as ibuprofen, acetaminophen, caffeine anhydride, aspirin,

ethenzamide, tolfenamic acid, mefenamic acid, phenacetin, flufenamic acid, salicylamide, aminopyrine, pentazocine, etc.; antiphlogistic agents such as serrapeptidase, lysozyme chloride, etc.; cardiotonics
5 such as dl-chlorpheniramine maleate, bupranolol hydrochloride, nitroglycerine, isosorbide nitrate, pindolol, propranolol hydrochloride, nifedipine, diltiazem hydrochloride, nisoldipine, benidipine hydrochloride, acebutolol hydrochloride, labetalol hydrochloride,
10 amlodipine besilate, verapamil hydrochloride, etc.; inorganics preparations such as potassium gluconate, calcium gluconate, sodium chloride, potassium chloride, calcium chloride, etc.; therapeutic agents for digestive ulcer such as glycopyrronium bromide,
15 proglumide, butylscopolamine bromide, benactyzine methobromide, propantheline bromide, cimetidine, famotidine, omeprazole, lansoprazole, oxethazaine, roxatidine acetate hydrochloride, L-glutamine, L-glutamate-water soluble azulene, sucralfate, etc.;

20 coronary vasodilators such as phenylpropanolamine hydrochloride, etc.; peripheral and cerebrovasodilators such as beraprost sodium, etc.; antihistamines such as diphenhydramine hydrochloride, etc.; therapeutic drugs for arterial hypertension such as uradipil, etc.;

25 antitussives-sedative expectrants such as dihydrocodeine phosphate, noscapine, methylephedrine hydrochloride, dextromethorphan hydrobromide, etc.;

therapeutic drugs for gout such as bucolome,

colchicine, probenecid, benzbromarone, sulfinpyrazone, allopurinol, etc.; bronchodilators such as aminophylline, theophylline, etc.; antidiabetic agents such as acetohexamie, glibenclamide, tolazamide, 5 tolbutamide, etc.; therapeutic drugs for pancreatitis such as camostat mesylate, etc.

The active ingredient itself may be employed for the present invention, or may be diluted with a diluent that is used generally in the pharmaceutical or 10 food industry. Examples of such diluents include lactose, anhydrous calcium hydrogenphosphate, crystalline cellulose, sucrose, D-mannitol, low substituted hydroxypropyl cellulose, xylitol, erythritol, trehalose, aspartame, etc. Among them, preferred are 15 lactose, anhydrous calcium hydrogenphosphate and crystalline cellulose.

Where the diluent is employed in the powders, the amount of the diluent to be used has no particular limitation and may vary depending on kind of the 20 pharmacologically active ingredient, but the diluent is used generally at least in a 5-fold amount by weight based on the pharmacologically active ingredient.

According to the present invention, the powders for surface modification comprising the 25 pharmacologically active ingredient described above or comprising the pharmacologically active ingredient and optionally further containing the diluent described above are subjected to surface modification with a

surface modifying base material to provide the pharmacologically active ingredient-comprising surface-modified powders having an improved flowability.

Any material can be used as the surface
5 modifying base material of the present invention so long as the material does not adversely affect the pharmacologically active ingredient and can improve flowability. Preferably, the surface modifying base materials are those capable of physically adhering to
10 the surface of the powders for surface modification thereby to contribute to improving flowability of the powders. Examples of such surface modifying base materials include light silicic anhydride, talc, stearic acid, magnesium stearate, calcium stearate,
15 starch, titanium oxide, citric acid, malic acid, adipic acid, hydrous silicon dioxide, calcium carbonate, etc. Preferred are light silicic anhydride, talc, stearic acid, magnesium stearate and calcium stearate, with light silicic anhydride being particularly preferred.
20 Also, the surface modifying base material has preferably a mean particle size of 10 μm or less; if desired, the surface modifying base material may be ground to powders, which may be provided for use as the base material.

25 For subjecting the surface-modifying powders comprising the aforesaid pharmacologically active ingredient or the active ingredient and the diluent to the surface modification with the surface modifying

base material to improve the flowability, the surface-modifying powders are thoroughly blended with the surface modifying base material. More specifically, the blending can be carried out by any of blending devices conventionally used for manufacturing pharmaceutical preparations such as devices for surface modification, high speed mixers, high speed agitation granulators, versatile mixer and so on. Examples of such devices include Mechanomill (manufactured by Okada Seiko Co., Ltd.) Vertical Granulator (manufactured by Powrex), High Speed Mixer (manufactured by Fukae Powtec), Hybridizer, Laboratory Matrix (manufactured by Nara Machinery Co., Ltd.), Theta Composer (manufactured by Tokuju Corporation), etc.

The amount of the surface modifying base material described above may vary depending upon kind of the pharmacologically active ingredient used but generally, the surface modifying base material is incorporated in the obtained active ingredient-comprising surface-modified powders in the amount of approximately 0.1 to 5 wt%, preferably about 1 to about 3 wt%.

In case that the pharmacologically active ingredient having a low melting point or of a sticky property, such as ibuprofen, is used in the present invention, it is preferred to add finely divided titanium oxide or talc powders to the active ingredient before or after the surface modification described

above at the following production steps, in order to improve tableting problems, i.e., sticking or binding in preparing, e.g., flat tablets. Also where a bitter or stinging active ingredient such as ibuprofen is
5 employed in the present invention, finely divided sweeteners such as erythritol or trehalose are advantageously added to the active ingredient, before or after the surface modification, in the same way as described above.

10 Preferably, the addition of these components is effected by a so-called multiple layer surface modification method, which involves adding these components to the powders comprising the pharmacologically active ingredient or the pharmacologically
15 active ingredient and the diluent before surface modification or to the pharmacologically active ingredient-comprising surface-modified powders after surface modification, and then dry coating the blend with a high speed mixer, a high speed agitation
20 granulator, a general-purpose kneader, etc. as described above.

 Preferably, the components of finely divided titanium oxide, talc, erythritol, trehalose, etc. described above have a mean particle size of 3 μ m or
25 less, and the amount of the finely divided components is in the range of 3 wt% or less, based on the total weight of the pharmacologically active surface-modified powders finally obtained.

The thus obtained pharmacologically active ingredient-comprising surface-modified powders generally have a particle size of approximately 20 to 200 μm , preferably about 40 to about 110 μm .

5 Where a pharmacologically active ingredient requiring only a small dose is used to produce the pharmacologically active ingredient-comprising surface-modified powders of the present invention, the following procedures are advantageously employed.

10 For example, when the pharmacologically active ingredient-comprising surface-modified powders are designed to contain 0.02 to 10 wt% of the active ingredient, a diluent such as lactose is added in the course of surface modification to produce the pharmacologically active ingredient-comprising surface-modified powders. Where lactose is used, large particles of lactose for direct tableting may be used. Suitable examples of the pharmacologically active ingredient used to produce such pharmacologically active ingredient-comprising surface-modified powders are glycopyrronium bromide, bupranolol hydrochloride and beraprost sodium.

20 Unless the effects contemplated in the invention are interfered with, the surface-modified powders may further contain a variety of additives, which are commonly used in the manufacture of pharmaceutical preparations. Specific examples of such additives will be described hereinafter.

The pharmacologically active ingredient-comprising surface-modified powders of the present invention described above in detail have an excellent flowability. The surface-modified powders of the present invention exhibit flowability at an angle of repose of 42° or less, and more preferably, at an angle of repose of 40° or less. Therefore, the pharmacologically active ingredient-comprising surface-modified powders enable to produce tablets by dry procedures using direct tableting. Thus, the powders can be used not only as substrates for producing the fast disintegrating tablets of the present invention described in the following section, but also as substrates for preparing tablets by dry procedures using other conventional direct tableting. These tablets may also be produced by, for example, admixing the pharmacologically active ingredient-comprising surface-modified powders of the present invention with conventional additives, and tableting the mixture with a direct tableting machine.

According to the present invention, by admixing the pharmacologically active ingredient-comprising surface-modified powders and a disintegrant and directly tableting the mixture, the fast disintegrating tablets of the present invention can be produced. The fast disintegrating tablet of the invention have an appropriate disintegratability and solubility, are disintegrated into a suitable size when

holding water in the oral cavity to cause no stick or choking to the throat and thus make oral medication easy to aged or pediatric patients.

The pharmacologically active ingredient-
5 comprising surface-modified powders may be used as admixture of a plurality of pharmacologically active ingredient-comprising surface-modified powders using different active components.

Sub B2
10 Specific examples of the disintegrants used in the present invention include partially alphanized starch, crospovidone (Polyplasdone), crystalline cellulose-carmellose sodium, low substituted hydroxypropyl cellulose, corn starch, potato and other starches, carmellose, carmellose calcium, carmellose sodium, croscarmellose sodium, carboxymethylstarch
15 sodium, etc. Among them, partially alphanized starch and crospovidone are particularly preferred.

The amount of the disintegrant which is mixed with the pharmacologically active ingredient-comprising
20 surface-modified powders may vary depending on kind of the active ingredient used, but the disintegrant is used in an amount of generally 10 to 60 wt%, preferably about 20 to 40 wt%, based on the weight of the tablet finally obtained.

25 When a smaller dose of the active ingredient is required as in therapeutic agents for angina pectoris, therapeutic drugs for digestive ulcer, peripheral vasodilators, etc. or a moderate dose is

required as for antiinflammatory-analgesic-antipyretic agents, the disintegrant is added in the amount of generally 10 to 60 wt%, and preferably about 20 to about 40%, based on the total weight of the tablet
5 finally obtained.

When inorganics or the like requiring a large dose are used as the pharmacologically active ingredient, the disintegrant is added in the amount of generally 10 to 40 wt%, and preferably about 20 to
10 about 30%, based on the total weight of the tablet finally obtained.

In addition to the disintegrant described above, the surface-modified powders may further contain a variety of additives conventionally employed in the
15 manufacture of tablets, unless the effects of the invention are interfered with these additives.

Such additives include, for example, binders, acids, foaming agents, artificial sweeteners, flavorings, lubricants, colorants and so on.

20 Examples of the binders include hydroxypropylcellulose, hydroxypropylmethylcellulose 2910, hydroxypropyl starch, gelatin, pullulan and the like. Examples of the acids include citric acid, tartaric acid, malic acid, adipic acid and so on. Examples of
25 the foaming agents include citric acid, sodium bicarbonate and so on. Examples of the artificial sweeteners include saccharin sodium, glycyrrhizic acid dipotassium salt, aspartame, stevia, thaumatin,

xylitol, erythritol, glucose, and so on. Examples of the flavorings include lemon, orange, grape fruit, grape, menthol, spearmint, peppermint, vanilla, cinnamon, and the like. Examples of the lubricants
5 include magnesium stearate, talc, sucrose fatty acid esters, polyethyleneglycol, stearic acid and the like. Examples of the colorants include various food colorants, e.g. FD & C Yellow No. 5, FD & C RED No.2, FD & C Blue No.2, etc., food lakes, red iron oxide and
10 so on.

One or more of these additives can be timely added in appropriate proportions, for example, at any step in the course of blending or before and after blending the pharmacologically active ingredient-
15 comprising surface-modified powders with the disintegrant.

In the present invention, it is advantageous to use, among others, crystalline cellulose (trade name: CEOLUS, manufactured by Asahikasei Corporation)
20 as the additive, in combination with the disintegrant, since the hardness of the tablets obtained is increased. Where crystalline cellulose is added to the powders, the hardness of the resulting tablet is enhanced, while the tablet retains its rapid disinte-
25 grating property. The crystalline cellulose is added to the powders to have a proportion of 10 to 70 wt%, based on the total weight of the tablet finally obtained.

The blending of the pharmacologically active ingredient-comprising surface-modified powders with the disintegrant and optionally additives can be carried out by any blending techniques such as mixing, kneading, sieving and so on, which are conventionally used in the course of manufacturing pharmaceutical preparations. Specifically, a V-Shaped Mixer, Gyro Shifter, Theta Composer (manufactured by Tokuju Corporation), Vertical Granulator (manufactured by Powrex), High Speed Mixer (manufactured by Fukae Powtec), Laboratory Matrix (manufactured by Nara Machinery Co., Ltd.), etc. can be employed.

For tabletting the blend or mixture thus obtained, devices conventionally used for molding of tablets can be employed. For example, a single tabletting machine, a rotary tabletting machine, a full-automated rotary tabletting machine (manufactured by Hata Iron Works), etc. are available.

In tabletting with the above tabletting machines, a compression pressure greatly changes depending on tablet size. When using a pestle of 8 mm in diameter, the compression pressure is generally set under 190 to 1,990 Kg/cm², with a pestle of 10 mm in diameter, generally under 250 to 1,920 Kg/cm², and with a pestle of 20 mm in diameter, generally under 520 to 1,320 Kg/cm². The tablet is compression-molded to have an appropriate strength well resistant to the steps of storage, packaging and transportation.

As described above, the fast disintegrating tablets of the present invention can be extremely readily produced by dry procedures using production devices conventionally available, without requiring any
5 complex step. Moreover, the thus produced fast disintegrating tablets are excellent in solubility and disintegratability.

The fast disintegrating tablets of the present invention have a suitable disintegratability
10 and solubility to be disintegrated to a desired size when holding water in the oral cavity so that the tablets are neither adhered to nor choked in the throat, and are easy for administration to aged or pediatric patients. Accordingly, the tablets of the
15 present invention can be advantageously used for the treatment and prevention of diseases in patients, particularly aged or pediatric patients.

Furthermore, the fast disintegrating tablets of the present invention are excellent in storage and
20 stability over a long period of time, because the tablets possess a desired strength. The tablets of the present invention retain a mechanical strength sufficient to resist destruction when the tablets are taken by the patient, for example, when they are taken out of
25 PTP packages. Therefore, the fast disintegrating tablets of the invention can be advantageously used for the patient who should be medicated depending on the active ingredient contained, for the treatment and

prevention of diseases in patients, particularly aged or pediatric patients.

Hereinafter, the present invention will be described in more detail, with reference to EXAMPLES
5 but is not deemed to be limited thereto.

EXAMPLE 1

A high speed agitation granulator (Laboratory Matrix LMA10, manufactured by Nara Machinery Co., Ltd.) was charged with 2 parts by weight of light silicic
10 anhydride based on 100 parts by weight of ibuprofen to examine the conditions for surface modification. A mean particle size became constant when the time for surface modification showed 15 minutes. Measurement of the angle of repose 25 minutes after revealed that
15 flowability was markedly improved. It was thus confirmed that the powders containing the original drug for direct tableting, namely, the pharmacologically active ingredient-comprising surface-modified powders of the present invention were obtained. The procedures
20 and results are shown in TABLE 1.

TABLE 1

<u>Time for Surface Modification (min.)</u>	<u>Mean Particle Size (μm)^{*1}</u>	<u>Angle of Repose ($^{\circ}$)^{*2}</u>
0	50.5	53
3	46.1	-
5	48.0	45
10	55.8	42
15	57.7	40
20	57.2	39
25	57.3	39

Conditions for surface modification:

main impeller: 300 rpm

granulation impeller: 1,500 rpm

*1: The mean particle size was measured using
5 a Laser diffraction size analyzer LDSA-1400A (manufactured by Tohnichi Computer Application Co., Ltd.).

*2: The angle of repose was measured with a powder tester (manufactured by Hosokawa Micron Co., Ltd.).

10 EXAMPLE 2

A high speed agitation granulator (Laboratory Matrix LMA10, manufactured by Nara Machinery Co., Ltd.) was charged with 1 part by weight of light silicic anhydride based on 100 parts by weight of potassium
15 gluconate to examine the conditions for surface modification in the same manner as in EXAMPLE 1. The

results are shown in TABLE 2.

TABLE 2

<u>Time for Surface</u> <u>Modification (min.)</u>	<u>Mean Particle</u> <u>Size (μm)</u>	<u>Angle of</u> <u>Repose (°)</u>
0	111.3	41
5	123.6	39
10	122.5	37
15	121.5	37

Conditions for surface modification:

main impeller: 300 rpm

granulation impeller: 1,500 rpm

- 5 Measurement of the mean particle size and angle of repose:

The same devices as in EXAMPLE 1 were used.

- The results of EXAMPLES 1 and 2 reveal that by adding light silicic anhydride to the pharmaco-
- 10 logically active ingredient to effect the surface modification, the flowability (angle of repose) of the pharmacologically active ingredient-comprising surface-modified powders of the present invention was markedly improved to give the flowability sufficient to perform
- 15 direct tableting continuously. The results further reveal that the time required for surface modification was at least 5 minutes, preferably 10 to 20 minutes.

Furthermore, the time required for surface modification can be judged by the time when the angle of repose becomes 40° or less.

The results of EXAMPLES 1 and 2 reveal that
5 when the active ingredient has a particle size of 20 μm or more, the surface-modified product with a good quality, i.e., the pharmacologically active ingredient-comprising surface-modified powders of the invention can be obtained, since the mean particle size of
10 ibuprofen and potassium gluconate were found to be 50.5 μm (10% particle size: 19.2 μm , 90% particle size: 101.6 μm) and 111.3 μm , respectively. The pharmacologically active ingredient of at least 50 μm is preferred for use in the present invention.

15 EXAMPLE 3

A high speed agitation granulator (Laboratory Matrix LMA10, manufactured by Nara Machinery Co., Ltd.) was charged with ibuprofen and light silicic anhydride in the respective amounts shown in TABLE 3 below.

20 Surface modification was performed for 25 minutes (conditions for the surface modification: a main impeller of 300 rpm, a granulation impeller of 1,500 rpm). Next, the whole amount of the pharmacologically active ingredient-comprising surface-modified powders
25 of the present invention obtained above were taken out of the granulator. The remaining components given in TABLE 3 below, i.e., citric acid, partially alphanized

starch (manufactured by Asahikasei Corporation, trade name: PCS), crystalline cellulose (manufactured by Asahikasei Corporation, Avicel PH301) and magnesium stearate were added to the powders, followed by mixing with a V-10 blender (manufactured by Tokuju Corporation) for 5 minutes. The mixture was tableted with a pestle of 10 mm in diameter and 7.5 mmR using a fully automated rotary tabletting machine (manufactured by Hata Iron Works). Thus, the fast disintegrating tablets of the present invention were produced. Flavorings, sweeteners and so on may be incorporated to improve the taste.

TABLE 3

Formulation

<u>Component</u>	<u>Amount Added (unit: g)</u>
Ibuprofen	800
Light silicic anhydride	16
Citric acid	200
Partially alphanized starch	956
Crystalline cellulose	380
Magnesium stearate	48
Total	2400

EXAMPLE 4

The same formulation as in EXAMPLE 3 was surface-modified under the same conditions as those of EXAMPLE 3 and the experiment was carried out in the same way, except that the disintegrant was changed to

crospovidone (the amount was the same). A high speed agitation granulator (Laboratory Matrix LMA10, manufactured by Nara Machinery Co., Ltd.) was charged with ibuprofen and light silicic anhydride in the
5 respective amounts indicated in TABLE 4 below. Surface modification was performed for 25 minutes (conditions for the surface modification: main impeller of 300 rpm, granulation impeller of 1,500 rpm). Next, the whole amount of the pharmacologically active ingredient-
10 comprising surface-modified powders of the present invention obtained above were taken out of the granulator. The remaining components given in TABLE 4 below, i.e., citric acid, crospovidone (manufactured by ISP Japan, trade name: Polyplasdone XL), crystalline
15 cellulose and magnesium stearate were added to the powders, followed by mixing with a V-10 blender (manufactured by Tokuju Corporation) for 5 minutes. The mixture was tableted with a pestle of 10 mm in diameter and 7.5 mmR using a fully automated rotary
20 tableting machine (manufactured by Hata Iron Works). Thus, the fast disintegrating tablets of the present invention were produced. Flavorings, sweeteners and so on may be incorporated to improve taste.

TABLE 4

Formulation	
<u>Component</u>	<u>Amount Added (unit: g)</u>
Ibuprofen	800
Light silicic anhydride	16
Citric acid	200
Crospovidone	956
Crystalline cellulose	380
Magnesium stearate	48
Total	2400

EXAMPLE 5

Sub B2
A high speed agitation granulator (Laboratory Matrix LMA10, manufactured by Nara Machinery Co., Ltd.) was charged with potassium gluconate and light silicic anhydride in the respective amounts indicated in TABLE 6 below. Surface modification was performed for 15 minutes (conditions for the surface modification: main impeller of 300 rpm, granulation impeller of 1,500 rpm). Next, the whole amount of the pharmacologically active ingredient-comprising surface-modified powders of the present invention obtained above were taken out of the granulator. The remaining components given in TABLE 5 below, i.e., partially alphanized starch, glucono delta lactone, erythritol, crystalline cellulose and magnesium stearate were added to the powders, followed by mixing with a V-10 blender (manufactured by Tokuju Corporation) for 5 minutes. The mixture was then tableted with a pestle for odd-

B3
shaped tablets (16 mm × 7 mm) using a fully automated rotary tabletting machine (manufactured by Hata Iron Works). Thus, the fast disintegrating tablets of the present invention were produced. Flavorings, 5 sweeteners and so on may be incorporated to improve taste.

TABLE 5

sub B4

Formulation	
<u>Component</u>	<u>Amount Added (unit: g)</u>
Potassium gluconate	500
Light silicic anhydride	5
Partially alphanized starch	215
Glucono delta lactone	12
Erythritol	50
Crystalline cellulose	100
Magnesium stearate	18
Total	900

EXAMPLE 6

A high speed agitation granulator (Laboratory Matrix LMA10, manufactured by Nara Machinery Co., Ltd.) was charged with potassium gluconate and light silicic anhydride in the respective amounts indicated in TABLE 6 below. Surface modification was performed for 15 minutes (conditions for the surface modification: main impeller of 300 rpm, granulation impeller of 1,500 rpm). Next, the whole amount of the pharmacologically active ingredient-comprising surface-modified powders of the present invention obtained above were taken out

of the granulator. The remaining components given in
 TABLE 6 below, i.e., crospovidone, glucono delta
 lactone, crystalline cellulose and magnesium stearate
 were added to the powders, followed by mixing with a V-
 5 10 blender (manufactured by Tokujin Corporation) for 5
 minutes. The mixture was then tableted with a pestle
 for odd-shaped tablets (19 mm X 8 mm) using a fully
 automated rotary tabletting machine (manufactured by
 Hata Iron Works). Thus, the fast disintegrating
 10 tablets of the present invention were produced.
 Flavorings, sweeteners and so on may be incorporated to
 improve taste.

TABLE 6

Formulation

<u>Component</u>	<u>Amount Added (unit: g)</u>
Potassium gluconate	1000
Light silicic anhydride	10
Crospovidone	238
Glucono delta lactone	24
Crystalline cellulose	100
Magnesium stearate	28
Total	1400

EXAMPLE 7

A high speed agitation granulator (Vertical
 15 Granulator FM-VG-01, manufactured by Powrex) was
 charged with bupranolol hydrochloride and lactose G.
 After blending with a main impeller and a granulation

impeller, both at 500 rpm for 1 minute, 2 wt% of light silicic anhydride was added and surface modification was conducted for 10 minutes under the same conditions. The remaining components given in TABLE 7 below, i.e.,

5 partially alphanized starch and magnesium stearate were added to the powders, followed by blending a Transparent Micro V-Mixer (manufactured by Tsutsui Scientific Instruments Co., Ltd.) for 15 minutes. The mixture was then tableted with a flat-faced beveled

10 edged pestle of 8.5 mm in diameter using a fully automated rotary tabletting machine (manufactured by Hata Iron Works). Thus, the fast disintegrating tablets of the present invention were produced. Flavorings, sweeteners and so on may be incorporated to

15 improve taste.

TABLE 7

Formulation	
<u>Component</u>	<u>Amount Added (unit: g)</u>
Bupranolol hydrochloride	10
Lactose G	107.6
Light silicic anhydride	2.4
Partially alphanized starch	89.2
Magnesium stearate	0.8
Total	210

EXAMPLE 8

A high speed agitation granulator (Vertical Granulator FM-VG-01, manufactured by Powrex) was

Sub
B5

charged with glycopyrronium bromide and lactose
(manufactured by Freund Industrial Co., Ltd., trade
name: DAI-LACTOSE S). After blending with a main
impeller and a granulation impeller, both at 500 rpm,
5 for 1 minute, 1 wt% of light silicic anhydride was
added and surface modification was conducted for 15
minutes under the same conditions. The remaining
components shown in TABLE 8 below, i.e., crystalline
cellulose, partially alphanized starch, erythritol and
10 magnesium stearate were added to the powders, followed
by blending a Transparent Micro V-Mixer (manufactured
by Tsutsui Scientific Instruments Co., Ltd.) for 15
minutes. The mixture was then tableted with a pestle
of 8.5 mm in diameter and 6.5R using a fully automated
15 rotary tableting machine (manufactured by Hata Iron
Works). Thus, the fast disintegrating tablets of the
present invention were produced. Flavorings,
sweeteners and so on may be incorporated to improve
taste.

b6
b7C
b7D
b7E
b7F
b7G
b7H
b7I
b7J
b7K
b7L
b7M
b7N
b7O
b7P
b7Q
b7R
b7S
b7T
b7U
b7V
b7W
b7X
b7Y
b7Z
b7AA
b7AB
b7AC
b7AD
b7AE
b7AF
b7AG
b7AH
b7AI
b7AJ
b7AK
b7AL
b7AM
b7AN
b7AO
b7AP
b7AQ
b7AR
b7AS
b7AT
b7AU
b7AV
b7AW
b7AX
b7AY
b7AZ
b7BA
b7BB
b7BC
b7BD
b7BE
b7BF
b7BG
b7BH
b7BI
b7BJ
b7BK
b7BL
b7BM
b7BN
b7BO
b7BP
b7BQ
b7BR
b7BS
b7BT
b7BU
b7BV
b7BW
b7BX
b7BY
b7BZ
b7CA
b7CB
b7CC
b7CD
b7CE
b7CF
b7CG
b7CH
b7CI
b7CJ
b7CK
b7CL
b7CM
b7CN
b7CO
b7CP
b7CQ
b7CR
b7CS
b7CT
b7CU
b7CV
b7CW
b7CX
b7CY
b7CZ
b7DA
b7DB
b7DC
b7DD
b7DE
b7DF
b7DG
b7DH
b7DI
b7DJ
b7DK
b7DL
b7DM
b7DN
b7DO
b7DP
b7DQ
b7DR
b7DS
b7DT
b7DU
b7DV
b7DW
b7DX
b7DY
b7DZ
b7EA
b7EB
b7EC
b7ED
b7EE
b7EF
b7EG
b7EH
b7EI
b7EJ
b7EK
b7EL
b7EM
b7EN
b7EO
b7EP
b7EQ
b7ER
b7ES
b7ET
b7EU
b7EV
b7EW
b7EX
b7EY
b7EZ
b7FA
b7FB
b7FC
b7FD
b7FE
b7FF
b7FG
b7FH
b7FI
b7FJ
b7FK
b7FL
b7FM
b7FN
b7FO
b7FP
b7FQ
b7FR
b7FS
b7FT
b7FU
b7FV
b7FW
b7FX
b7FY
b7FZ
b7GA
b7GB
b7GC
b7GD
b7GE
b7GF
b7GG
b7GH
b7GI
b7GJ
b7GK
b7GL
b7GM
b7GN
b7GO
b7GP
b7GQ
b7GR
b7GS
b7GT
b7GU
b7GV
b7GW
b7GX
b7GY
b7GZ
b7HA
b7HB
b7HC
b7HD
b7HE
b7HF
b7HG
b7HH
b7HI
b7HJ
b7HK
b7HL
b7HM
b7HN
b7HO
b7HP
b7HQ
b7HR
b7HS
b7HT
b7HU
b7HV
b7HW
b7HX
b7HY
b7HZ
b7IA
b7IB
b7IC
b7ID
b7IE
b7IF
b7IG
b7IH
b7II
b7IJ
b7IK
b7IL
b7IM
b7IN
b7IO
b7IP
b7IQ
b7IR
b7IS
b7IT
b7IU
b7IV
b7IW
b7IX
b7IY
b7IZ
b7JA
b7JB
b7JC
b7JD
b7JE
b7JF
b7JG
b7JH
b7JI
b7JJ
b7JK
b7JL
b7JM
b7JN
b7JO
b7JP
b7JQ
b7JR
b7JS
b7JT
b7JU
b7JV
b7JW
b7JX
b7JY
b7JZ
b7KA
b7KB
b7KC
b7KD
b7KE
b7KF
b7KG
b7KH
b7KI
b7KJ
b7KK
b7KL
b7KM
b7KN
b7KO
b7KP
b7KQ
b7KR
b7KS
b7KT
b7KU
b7KV
b7KW
b7KX
b7KY
b7KZ
b7LA
b7LB
b7LC
b7LD
b7LE
b7LF
b7LG
b7LH
b7LI
b7LJ
b7LK
b7LL
b7LM
b7LN
b7LO
b7LP
b7LQ
b7LR
b7LS
b7LT
b7LU
b7LV
b7LW
b7LX
b7LY
b7LZ
b7MA
b7MB
b7MC
b7MD
b7ME
b7MF
b7MG
b7MH
b7MI
b7MJ
b7MK
b7ML
b7MM
b7MN
b7MO
b7MP
b7MQ
b7MR
b7MS
b7MT
b7MU
b7MV
b7MW
b7MX
b7MY
b7MZ
b7NA
b7NB
b7NC
b7ND
b7NE
b7NF
b7NG
b7NH
b7NI
b7NJ
b7NK
b7NL
b7NM
b7NN
b7NO
b7NP
b7NQ
b7NR
b7NS
b7NT
b7NU
b7NV
b7NW
b7NX
b7NY
b7NZ
b7OA
b7OB
b7OC
b7OD
b7OE
b7OF
b7OG
b7OH
b7OI
b7OJ
b7OK
b7OL
b7OM
b7ON
b7OO
b7OP
b7OQ
b7OR
b7OS
b7OT
b7OU
b7OV
b7OW
b7OX
b7OY
b7OZ
b7PA
b7PB
b7PC
b7PD
b7PE
b7PF
b7PG
b7PH
b7PI
b7PJ
b7PK
b7PL
b7PM
b7PN
b7PO
b7PP
b7PQ
b7PR
b7PS
b7PT
b7PU
b7PV
b7PW
b7PX
b7PY
b7PZ
b7QA
b7QB
b7QC
b7QD
b7QE
b7QF
b7QG
b7QH
b7QI
b7QJ
b7QK
b7QL
b7QM
b7QN
b7QO
b7QP
b7QQ
b7QR
b7QS
b7QT
b7QU
b7QV
b7QW
b7QX
b7QY
b7QZ
b7RA
b7RB
b7RC
b7RD
b7RE
b7RF
b7RG
b7RH
b7RI
b7RJ
b7RK
b7RL
b7RM
b7RN
b7RO
b7RP
b7RQ
b7RR
b7RS
b7RT
b7RU
b7RV
b7RW
b7RX
b7RY
b7RZ
b7SA
b7SB
b7SC
b7SD
b7SE
b7SF
b7SG
b7SH
b7SI
b7SJ
b7SK
b7SL
b7SM
b7SN
b7SO
b7SP
b7SQ
b7SR
b7SS
b7ST
b7SU
b7SV
b7SW
b7SX
b7SY
b7SZ
b7TA
b7TB
b7TC
b7TD
b7TE
b7TF
b7TG
b7TH
b7TI
b7TJ
b7TK
b7TL
b7TM
b7TN
b7TO
b7TP
b7TQ
b7TR
b7TS
b7TT
b7TU
b7TV
b7TW
b7TX
b7TY
b7TZ
b7UA
b7UB
b7UC
b7UD
b7UE
b7UF
b7UG
b7UH
b7UI
b7UJ
b7UK
b7UL
b7UM
b7UN
b7UO
b7UP
b7UQ
b7UR
b7US
b7UT
b7UU
b7UV
b7UW
b7UX
b7UY
b7UZ
b7VA
b7VB
b7VC
b7VD
b7VE
b7VF
b7VG
b7VH
b7VI
b7VJ
b7VK
b7VL
b7VM
b7VN
b7VO
b7VP
b7VQ
b7VR
b7VS
b7VT
b7VU
b7VV
b7VW
b7VX
b7VY
b7VZ
b7WA
b7WB
b7WC
b7WD
b7WE
b7WF
b7WG
b7WH
b7WI
b7WJ
b7WK
b7WL
b7WM
b7WN
b7WO
b7WP
b7WQ
b7WR
b7WS
b7WT
b7WU
b7WV
b7WW
b7WX
b7WY
b7WZ
b7XA
b7XB
b7XC
b7XD
b7XE
b7XF
b7XG
b7XH
b7XI
b7XJ
b7XK
b7XL
b7XM
b7XN
b7XO
b7XP
b7XQ
b7XR
b7XS
b7XT
b7XU
b7XV
b7XW
b7XX
b7XY
b7XZ
b7YA
b7YB
b7YC
b7YD
b7YE
b7YF
b7YG
b7YH
b7YI
b7YJ
b7YK
b7YL
b7YM
b7YN
b7YO
b7YP
b7YQ
b7YR
b7YS
b7YT
b7YU
b7YV
b7YW
b7YX
b7YY
b7YZ
b7ZA
b7ZB
b7ZC
b7ZD
b7ZE
b7ZF
b7ZG
b7ZH
b7ZI
b7ZJ
b7ZK
b7ZL
b7ZM
b7ZN
b7ZO
b7ZP
b7ZQ
b7ZR
b7ZS
b7ZT
b7ZU
b7ZV
b7ZW
b7ZX
b7ZY
b7ZZ

TABLE 8

Formulation		
	<u>Component</u>	<u>Amount Added (unit: g)</u>
	Glycopyrronium bromide	1
	Lactose	99
	Light silicic anhydride	1
	Crystalline cellulose	30
	Partially alphanized starch	100
	Erythritol	16.5
	Magnesium stearate	2.5
	Total	250

EXAMPLE 9

1) A high speed agitation granulator
(Vertical Granulator FM-VG-01, manufactured by Powrex)
was charged with ibuprofen and 2 wt% of light silicic
5 anhydride based on ibuprofen. Surface modification was
conducted for 25 minutes under the following condi-
tions: a main impeller at 500 rpm and a granulation
impeller at 500 rpm.

2) Next, a high speed agitation granulator
10 (Vertical Granulator FM-VG-01, manufactured by Powrex)
was charged with acetaminophen and 2 wt% of light
silicic anhydride based on acetaminophen. Surface
modification was conducted for 25 minutes under the
following conditions: a main impeller at 500 rpm and a
15 granulation impeller at 500 rpm.

3) Next, a high speed agitation granulator
(Vertical Granulator FM-VG-01, manufactured by Powrex)

was charged with anhydrous caffeine and 2 wt% of light silicic anhydride based on anhydrous caffeine. Surface modification was conducted for 25 minutes under the following conditions: a main impeller at 500 rmp and a
5 granulation impeller at 500 rpm.

sub
B8

4) The remaining components shown in TABLE 9 below, i.e., citric acid, partially alphanized starch, lactose, crystalline cellulose and magnesium stearate were added to the respective three pharmacologically
10 active ingredient-comprising surface-modified powders, followed by blending a V-10 blender (manufactured by Tokuju Corporation) for 5 minutes. Each mixture was then tableted with a pestle of 10 mm in diameter and 7.5 mmR using a fully automated rotary tableting
15 machine (manufactured by Hata Iron Works). Thus, the fast disintegrating tablets of the present invention were produced. Flavorings, sweeteners and so on may be incorporated to improve taste.

TABLE 9

Formulation

<u>Component</u>	<u>Amount Added (unit: g)</u>
Ibuprofen	75
Acetaminophen	150
Anhydrous caffeine	60
Light silicic anhydride	5.7
Citric acid	20
Partially alphanized starch	232.3
Lactose	100
Crystalline cellulose	50
Magnesium stearate	7
Total	700

TEST EXAMPLE 1

In order to explain the effects achieved by the present invention in more detail, tablet characteristics were determined with the fast disintegrating tablets of the invention obtained in EXAMPLES and commercial products, and comparison was made between the tablets of the invention and the commercial products. The results are shown in TABLES 10 and 11. It is understood by comparing TABLES 10 and 11 that the fast disintegrating tablets obtained in the present invention are excellent in disintegratability and yet maintain a suitable strength. It is also confirmed that partially alphanized starch and crospovidone were most suitable as the disintegrant.

Characteristic data of the experimental tablets
prepared in EXAMPLES:

TABLE 10

No. Example	1-1 3	1-2 4	2-1 5	2-2 6	3 7	4 8	5 9
Weight (mg)	300	300	900	1400	210	250	350
Thickness of tablet (mm)	5.4	5.2	6.2	9.2	5.1	6.0	5.8
Diameter of tablet (mm)	10.1	10.1	16×7	19×8	8.6	8.6	10.1
Hardness (kg)	4.0	6.0	4.8	6.1	3.1	2.7	5.3
Disintegration time (1)	29 secs.	15 secs.	120 secs.	29 secs.	45 secs.	30 secs.	34 secs.
Disintegration time (2)	62 secs.	37 secs.	186 secs.	120 secs.	79 secs.	30 secs.	58 secs.

Hardness:

The hardness is expressed as a mean value of
5 five measurements as measured with Kiya type Hardness
Tester.

(Hardness tester: HARDNESS TESTER (manufac-
tured by KIYA))

Disintegration time (1):

10 The disintegration time was measured with a
disintegration tester specified in The Pharmacopoeia of
Japan, 13th edition (no disk). The results indicate a
mean value of six runs.

(Disintegration tester: table disintegration
15 tester T-4H (manufactured by Toyama Sangyo Co., Ltd.))

Disintegration time (2):

A sieve of 5.5 mesh was put in a beaker charged with 300 mL of water. One tablet was placed in the beaker. The total elapsed time required for the
5 tablet to disintegrate, completely pass through the sieve and fall out of the mesh was recorded (distilled water: 23°C). The disintegration time is the average of the time recorded for 2 runs.

Characteristic data of the commercial products:

TABLE 11

No. of Commercial Tablet	Tablet 1	Tablet 2	Tablet 3	Tablet 4
Preparation form	Dragee	Film-coated	Film-coated	Uncoated
Weight (mg)	224	1245	178	203
Thickness of tablet (mm)	4.8	7.6	4.5	2.7
Diameter of tablet (mm)	8.1	19×8	7.7	8.6
Hardness (kg)	6.9	≥20	9.1	4.5
Disintegration time (1)	10 mins.	≥30 mins.	3 mins.	1 min.
Disintegration time (2)	≥30 mins.	≥30 mins.	7 mins.	80 secs.

10 Hardness:

The hardness is expressed as a mean value of five measurements as measured with Kiya type Hardness Tester.

(Hardness tester: HARDNESS TESTER (manufactured by KIYA))
15

Disintegration time (1):

The disintegration time was measured with a disintegration tester specified in The Pharmacopoeia of Japan, 13th edition (no disk). The results indicate a mean value of six runs.

(Disintegration tester: table disintegration tester T-4H (manufactured by Toyama Sangyo Co., Ltd.))

Disintegration time (2):

A sieve of 5.5 mesh was put in a beaker charged with 300 mL of water. One tablet was placed in the beaker. The total elapsed time required for the tablet to disintegrate, completely pass through the sieve and fall out of the mesh was recorded (distilled water: 23°C). The disintegration time is the average of the time recorded for 2 runs.

EXAMPLE 10

The blended powders produced in EXAMPLE 3 were tableted with a pestle having flat-faced beveled edges of 10 mm in diameter. Tableting problem (sticking to the pestle) was observed.

The material stuck to the pestle was found to be ibuprofen. It was considered to be caused by difference in shape of the pestle.

In order to solve the tableting problem, titanium oxide (manufactured by Toho Titanium K.K., trade name: Highly Pure Titanium Oxide) was coated onto

the surface of the surface-modified powders to form multiple layers. Thus, the fast disintegrating tablets could be produced.

The procedures for producing the fast
5 disintegrating tablets are described below.

A high speed agitation granulator (Laboratory Matrix LMA10, manufactured by Nara Machinery Co., Ltd.) was charged with ibuprofen and light silicic anhydride in the respective amounts shown in TABLE 12 below.

10 Surface modification was performed for 25 minutes (conditions for the surface modification: a main impeller of 300 rpm, a granulation impeller of 1,500 rpm). Next, titanium oxide having a mean particle size of 2.1 μm was added as indicated in TABLE 12 below to
15 perform dry coating for 5 minutes under the same conditions. Thus, the multilayered surface-modified powders with titanium oxide coating on the surface of the powders were prepared.

Sub B10
20 Thereafter, the whole amount of the pharmacologically active ingredient-comprising surface-modified powders of the present invention obtained above were taken out of the granulator. The remaining components given in TABLE 12 below, i.e., citric acid (manufactured by Wako Pure Chemical Industries Ltd.),
25 partially alphanized starch (manufactured by Asahikasei Corporation), crystalline cellulose (manufactured by Asahikasei Corporation, CEOLUS), talc (manufactured by Shokozan Mining Co., Ltd.) and magnesium stearate

(manufactured by Kyodo Yakuhin K.K.) were added to the powders, followed by mixing with a V-10 blender (manufactured by Tokuju Corporation) for 5 minutes. By tabletting the mixture with a pestle of 10 mm in diameter having flat-faced beveled edges using a tabletting machine, the tabletting problem was eliminated. Thus, the fast disintegrating tablets of the present invention were produced. The results indicate that by the multilayered surface modifying procedures, there could be obtained the fast disintegrating tablets available for low melting or strongly sticky drugs, irrespective of the shape of a pestle.

TABLE 12

Formulation		
	<u>Component</u>	<u>Amount Added (unit: g)</u>
	Ibuprofen	800
	Light silicic anhydride	8
	Titanium oxide	24
	Citric acid	136
	Partially alphanized starch	956
	Crystalline cellulose	380
	Magnesium stearate	48
	Talc	48
	Total	2400

EXAMPLE 11

Taste comparison was performed with the tablets prepared in EXAMPLE 10. A strongly stinging

taste spread over the entire tongue. The irritating component was found to be ibuprofen.

Therefore, an attempt to mask the stinging taste of the ibuprofen-containing fast disintegrating tablets and change them to compatible medicaments easy to be taken was made to alleviate the irritation of a drug particle carrier by multilayered surface modifying technique using the surface modification in combination with dry coating as in EXAMPLE 10. Finely divided erythritol (mean particle size: 1.3 μm) was used to reduce the stinging taste of ibuprofen. Erythritol was again added to the powders at the final stage to improve the taste.

The procedures of making pharmaceutical preparations with an improved taste and further functioning as a fast disintegrating tablet are described below.

A high speed agitation granulator (Laboratory Matrix LMA10, manufactured by Nara Machinery Co., Ltd.) was charged with ibuprofen and light silicic anhydride in the respective amounts shown in TABLE 13 below. Surface modification was performed for 25 minutes (conditions for the surface modification: a main impeller of 300 rpm, a granulation impeller of 1,500 rpm). Next, titanium oxide having a mean particle size of 2.1 μm and as a sweetener, erythritol finely divided with a jet mill in a mean particle size of 1.3 μm were added as indicated in TABLE 13 below to perform dry

coating for 5 minutes under the same conditions. Thus, the multilayered surface-modified powders, on the surface of which titanium oxide and jet mill-grounded erythritol had been coated were prepared.

5 Then, the whole amount of the pharmacologically active ingredient-comprising surface-modified powders of the present invention obtained above were taken out of the granulator. The remaining components given in TABLE 13 below, namely, citric acid
10 (manufactured by Wako Pure Chemical Industries Ltd.), partially alphanized starch (manufactured by Asahikasei Corporation), crystalline cellulose (manufactured by Asahikasei Corporation, CEOLUS), talc (manufactured by Shokozan Mining Co., Ltd.), erythritol (manufactured by
15 Nikken Chemical Industry Co., Ltd.), a flavoring agent (manufactured by Ogawa Perfumery Co., Ltd.) and magnesium stearate (manufactured by Kyodo Yakuhin K.K.) were added to the powders, followed by blending with a V-10 blender (manufactured by Tokuju Corporation) for 5
20 minutes. Any tableting problem that might be caused by tableting the blend with a pestle of 10 mm in diameter having flat-faced beveled edges using a tableting machine was not noted. Moreover, the thus produced fast disintegrating tablets of the present
25 invention were improved on the stinging taste. The results indicate that by the multilayered surface modifying technique, the fast disintegrating tablets were found to be available for improving the taste of

drugs having a bitter or stinging taste.

TABLE 13

Formulation	
<u>Component</u>	<u>Amount Added (unit: g)</u>
Ibuprofen	400
Light silicic anhydride	4
Titanium oxide	4
Finely divided erythritol	12
Citric acid	40
Erythritol	400
Partially alphanized starch	480
Crystalline cellulose	1000
Flavoring agent (orange)	12
Magnesium stearate	24
Talc	24
Total	2400

EXAMPLE 12

It was examined if the order of the multi-layered surface modification technique used in EXAMPLE 12, namely, the surface modification and dry coating, would affect the tablet characteristics. For the comparison purpose, the same formulation as that of EXAMPLE 11 was used in this EXAMPLE.

The procedures are described below.

A high speed agitation granulator (Laboratory Matrix LMA10, manufactured by Nara Machinery Co., Ltd.) was charged with ibuprofen, titanium oxide having a mean particle diameter of 2.1 μm and finely divided erythritol (a mean particle size: 1.3 μm) in the

respective amounts shown in TABLE 14 below. Dry coating was performed for 5 minutes (a main impeller of 300 rpm, a granulation impeller of 1,500 rpm).

Subsequently, light silicic anhydride was added to the blend as indicated in TABLE 14 below. Surface modification was performed for 25 minutes under the same conditions to produce the multilayered surface-modified powders containing the anti-adhesion agent and the sweetener.

10 Next, the whole amount of the pharmacologi-
cally active ingredient-comprising surface-modified
powders of the present invention obtained above were
taken out of the granulator. The remaining components
given in TABLE 14 below, namely, citric acid (manufac-
15 tured by Wako Pure Chemical Industries Ltd.), partially
alphanized starch (manufactured by Asahikasei Corpora-
tion), crystalline cellulose (manufactured by
Asahikasei Corporation, CELULUS), talc (manufactured by
Shokozan Mining Co., Ltd.), erythritol (manufactured by
20 Nikken Chemical Industry Co., Ltd.), a flavoring agent
(manufactured by Ogawa Perfumery Co., Ltd.) and
magnesium stearate (manufactured by Kyodo Yakuhin K.K.)
were added to the powders, followed by blending with a
V-10 blender (manufactured by Tokuju Corporation) for 5
25 minutes. The blend was tableted with a pestle of 10 mm
in diameter having flat-faced beveled edges using a
tableting machine but no tableting problem was noted.
Moreover, the thus produced fast disintegrating tablets

Sub
B-10
of
the
tablets

of the present invention had a quality equivalent to those obtained in EXAMPLE 11 in terms of improvement in the stinging taste. The results indicate that by the multilayered surface modifying technique, the fast disintegrating tablets were found to be available not only for low melting or strongly sticky drugs but also for improving the taste of drugs having a bitter or stinging taste. It was confirmed that even if the order of adding the surface modifiers is changed, the tablet preparations can be obtained with an equivalent quality.

TABLE 14

Formulation		
<u>Component</u>	<u>Amount Added (unit: g)</u>	
Ibuprofen	400	
Titanium oxide	4	
Finely divided erythritol	12	
Light silicic anhydride	4	
Citric acid	40	
Erythritol	400	
Partially alphanized starch	480	
Crystalline cellulose	1000	
Flavoring agent (orange)	12	
Magnesium stearate	24	
Talc	24	
Total	2400	

EXAMPLE 13

Using trehalose instead of the sweetener

erythritol used in EXAMPLES 11 and 2, it was examined if kind of the sweetener would affect the tablet characteristics. The multilayered surface modifying technique, namely, the order and formulation of the surface modification and the dry coating were the same as in EXAMPLE 12.

The procedures are described below.

A high speed agitation granulator (Laboratory Matrix LMA10, manufactured by Nara Machinery Co., Ltd.) was charged with ibuprofen, titanium oxide having a mean particle diameter of 2.1 μm and finely divided trehalose (a mean particle size: 1.4 μm) (manufactured by Asahikasei Corporation) in the respective amounts shown in TABLE 15 below. Dry coating was performed for 5 minutes (a main impeller of 300 rpm, a granulation impeller of 1,500 rpm).

Subsequently, light silicic anhydride was added to the blend as indicated in TABLE 15 below. Surface modification was performed for 25 minutes under the same conditions to produce the multilayered surface-modified powders containing the anti-adhesion agent and the sweetener.

Next, the whole amount of the pharmacologically active ingredient-comprising surface-modified powders of the present invention obtained above were taken out of the granulator. The remaining components given in TABLE 15 below, namely, citric acid (manufactured by Wako Pure Chemical Industries Ltd.), partially

Sub
B13

alphanized starch (manufactured by Asahikasei Corpora-
tion), crystalline cellulose (manufactured by
Asahikasei Corporation, CEOLUS), talc (manufactured by
Shokozan Mining Co., Ltd.), erythritol (manufactured by
5 Nikken Chemical Industry Co., Ltd.), a flavoring agent
(manufactured by Ogawa Perfumery Co., Ltd.) and
magnesium stearate (manufactured by Kyodo Yakuin K.K.)
were added to the powders, followed by blending with a
V-10 blender (manufactured by Tokuju Corporation) for 5
10 minutes. The blend was tableted with a pestle of 10 mm
in diameter having flat-faced beveled edges using a
tableting machine but no tableting problem was noted.
The thus produced fast disintegrating tablets had a
quality comparable to those obtained in EXAMPLE 12,
15 indicating that trehalose is likewise available for the
multilayered surface modification technique.

TABLE 15

Formulation	
<u>Component</u>	<u>Amount Added (unit: g)</u>
Ibuprofen	400
Titanium oxide	4
Finely divided trehalose	12
Light silicic anhydride	4
Citric acid	40
Erythritol	400
Partially alphanized starch	480
Crystalline cellulose	1000
Flavoring agent (orange)	12
Magnesium stearate	24
Talc	24
Total	2400

TEST EXAMPLE 2

In order to explain the effects achieved by the present invention in more detail, tablet characteristics were determined with the fast disintegrating tablets of the invention obtained in EXAMPLES 10 through 13. The results are shown in TABLE 16. The results reveal that the fast disintegrating tablets obtained in the present invention are excellent in disintegratability and yet maintain a suitable strength. No tableting problem (sticking to the pestle) was noted with the tablets obtained in EXAMPLES 10 to 13 and with the fast disintegrating tablets obtained in EXAMPLES 11 to 13, even the strongly stinging taste of ibuprofen was improved.

TABLE 16

Example	10	11	12	13
Pestle	10 mm ϕ , flat-faced beveled edge			
Sticking to pestle	none	none	none	none
Weight (mg)	300	300	300	300
Thickness of tablet (mm)	3.5	3.5	3.5	3.5
Diameter of tablet (mm)	10.2	10.1	10.1	10.2
Hardness (kg)	7.6	8.5	7.1	8.8
Disintegration time (1)	23 secs.	26 secs.	22 secs.	25 secs.
Disintegration time (2)	70 secs.	74 secs.	70 secs.	73 secs.
Taste (stinging)	yes	none ^{*1}	none	none

Hardness:

The hardness is expressed as a mean value of five measurements as measured with Kiya type Hardness Tester.

5 (Hardness tester: HARDNESS TESTER (manufactured by KIYA))

Disintegration time (1):

The disintegration time was measured with a disintegration tester specified in The Pharmacopoeia of Japan, 13th edition (no disk). The results indicate a mean value of six runs.

(Disintegration tester: table disintegration tester T-4H (manufactured by Toyama Sangyo Co., Ltd.))

Disintegration time (2):

15 A sieve of 5.5 mesh was put in a beaker charged with 300 mL of water. One tablet was placed in

the beaker. The total elapsed time required for the tablet to disintegrate, completely pass through the sieve and fall out of the mesh was recorded (distilled water: 23°C). The disintegration time is the average
5 of the time recorded for 2 runs.

*1: When taken together with water, there was no stinging taste and the stinging taste was alleviated when taken without water.

INDUSTRIAL APPLICABILITY

10 The fast disintegrating tablets of the present invention can be produced by the dry method in an extremely simple way, without requiring any complex procedures, using conventionally available devices/
equipments. Moreover, the thus produced fast
15 disintegrating tablets exhibit excellent dissolution and disintegration properties.

The fast disintegrating tablets of the present invention have a suitable disintegratability and solubility to be disintegrated to an appropriate
20 size when holding water in the oral cavity so that the tablets are neither adhered to nor choked in the throat, and are easy for administration to aged or pediatric patients, and thus are advantageously used for the prevention or treatment of diseases in
25 patients, particularly aged and pediatric patients.

The fast disintegrating tablets of the present invention have a sufficient strength and thus,

are excellent for storage and stability over a long period of time. The fast disintegrating tablets of the invention yet maintain a strength sufficient to resist destruction upon administration, for example, when they
5 are taken out of PTP packages. Therefore, the tablets of the invention can be advantageously used for the prevention or treatment of diseases in patients, particularly aged and pediatric patients.

Furthermore, by subjecting the pharmacologi-
10 cally active ingredients to surface modification using the surface modifying base material including light silicic anhydride, the pharmacologically active ingredient-comprising surface-modified powders having a good flowability can be obtained. The powders enable
15 to produce the fast disintegrating tablets of the present invention by the dry production method.

Moreover, the multilayered surface modification technique by the dry coating in combination with the aforesaid surface modification using titanium oxide
20 or erythritol having a mean particle size of 3 μm or less enables to produce tablets free of any tableting problem and also enables to produce tablets with an improved taste.